Journal of the National Comprehensive Cancer Network · 2020 · 128 citations · 37 references
MedicineHematologyOncologyCancer PreventionChemotherapyHematologic OncologyFebrile Neutropenia ManagementHematologic Malignancy TherapyNeutropenia ManagementBiosimilar Granulocyte Colony-stimulating Factor UseColony-stimulating Factor ProphylaxisFebrile Neutropenia Risk AssessmentFebrile Neutropenia TreatmentGranulocyte Colony-stimulating Factor AdministrationGrowth FactorsNeutropenia ProphylaxisSupportive Cancer Care
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
37
Charles L. Vogel, Marek Z. Wojtukiewicz, Robert R. Carroll et al. · Journal of Clinical Oncology · 2005 · 481 citations · Full text
Medicine, Oncology, Pharmacology +16